CD38 and neoplasm: Additionally, CD38‐EVs‐Dox induced significantly greater cytotoxicity against the tumour cells than EVs‐Dox in vitro, and CD38‐EVs‐DoxMNs significantly reduced tumour burden compared to both EVs‐DoxMNs and CD38‐EVs‐Doxi.v, while maintaining favourable safety profiles.